Sutro Biopharma (NASDAQ:STRO) Rating Increased to Overweight at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Sutro Biopharma (NASDAQ:STRO) from an equal weight rating to an overweight rating in a report released on Tuesday morning, MarketBeat.com reports. They currently have $27.00 price objective on the stock, up from their prior price objective of $8.00.

STRO has been the subject of a number of other reports. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and increased their price objective for the company from $10.00 to $28.00 in a report on Tuesday. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research report on Tuesday, January 20th. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Finally, Wedbush reiterated a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Sutro Biopharma has an average rating of “Hold” and a consensus target price of $34.33.

Sutro Biopharma Trading Up 10.5%

NASDAQ:STRO opened at $23.57 on Tuesday. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54. The stock has a 50-day moving average price of $18.39 and a 200 day moving average price of $12.68. The stock has a market capitalization of $200.58 million, a P/E ratio of -0.90 and a beta of 1.47.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Monday, March 23rd. The company reported ($5.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.66) by ($0.73). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The business had revenue of $11.65 million for the quarter, compared to the consensus estimate of $9.26 million. On average, research analysts predict that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sutro Biopharma

A number of large investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC grew its holdings in Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares during the last quarter. Invesco Ltd. lifted its stake in Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after purchasing an additional 53,390 shares during the last quarter. Cerity Partners LLC boosted its position in shares of Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after buying an additional 66,372 shares during the period. Qube Research & Technologies Ltd purchased a new position in shares of Sutro Biopharma during the second quarter valued at approximately $82,000. Finally, State of Tennessee Department of Treasury bought a new position in shares of Sutro Biopharma during the fourth quarter valued at approximately $86,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Two analyst upgrades with much higher price targets — HC Wainwright moved from Neutral to Buy and set a $28 target; Wells Fargo upgraded to Overweight with a $27 target — signaling renewed broker confidence and providing fresh buy-side impetus. Article Title
• Positive Sentiment: Pipeline progress: company reported dosing three cohorts in the Phase 1 trial of STRO-004 (TF ADC) and remains on track to report initial clinical data in mid‑2026 — a near‑term binary catalyst that can materially re-rate the stock if data are positive. Article Title
• Neutral Sentiment: Revenue beat: Sutro reported revenue of $11.65M versus analyst expectations of $9.26M, showing commercial or partnership receipts stronger than modeled — a positive data point, but offset by large GAAP losses. Press Release
• Neutral Sentiment: Short-interest data released for March shows zero reported short shares (and nonsensical NaN changes/days-to-cover numbers) — this appears to be a reporting/data issue and should not be interpreted as an actual clean short position. No reliable impact indicated.
• Negative Sentiment: Large EPS miss: Sutro reported a (-$5.39) EPS, missing consensus (-$4.66) by $0.73 and showing a very negative net margin and ROE — a reminder of high burn and continued operating losses that keep dilution risk and financing needs on the table. Press Release

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.